Gene Editing was one of the hottest genetic news topics in 2015. A simple, powerful emergent technology (called CRISPR-Cas9) made this once elusive goal suddenly a reality for nearly any laboratory.
Find out how a laboratory at Harvard University is using gene editing to treat mice with a genetic muscle disease (Duchenne Muscular Dystrophy).
Join us on channel 9 in Cambridge, every 2nd and 4th Wednesday at 6:30pm EST. Not living in Cambridge, or you don’t have a TV? No worries, you can find it on our YouTube station a day or so later.
About our guest:
Dr. Sharif Tabebordbar is a post-doctoral fellow in the laboratory of Dr. Amy Wagers at Harvard Department of Stem Cell and Regenerative Biology. His research is focused on improving stem cell-based therapies and producing novel gene therapy for treating genetic muscle diseases. He is also a co-organizer of Strength, Science and Stories of Inspiration, an annual event aimed at raising awareness for muscle diseases, facilitating interactions between stakeholders in the neuromuscular disease community and inspiring the next generation of scientists to join the fight.
About the host:
Kayla Sheets is the producer and host of THE VIBRANT GENE. She is a genetic counselor and founder of Vibrant Gene Consulting, a concierge practice located in Cambridge Massachusetts. Kayla is specialized in taking genetic insights and translating them into greater health and wellness for her clients. She also provides expert advice about parental DNA testing to confirm relationships when traditional paternity/maternity tests fail.
Production Assistants: Hayley Green and Margaret Emmet, are interns at the Master of Science Program in Genetic Counseling at the Boston University School of Medicine.
A special thanks to Beth Parks and Beth Kim for their key insights.
We have received overwhelmingly positive responses from viewers about our new show. Thank you for your comments and wonderful feedback! Have a suggestion for a future program? Connect with the host, and join Vibrant Gene’s e-community on FB, Twitter, LinkedIn.